The study, published in Breast Cancer Research and Treatment, retrospectively analyzed 87 women with metastatic triple-negative breast cancer who received Trop-2 antibody-drug conjugates between April 2020 and December 2025. Nearly all patients were treated with sacituzumab govitecan, an antibody-drug conjugate that links a topoisomerase I inhibitor payload to an antibody targeting Trop-2, a cell-surface protein abundantly expressed in triple-negative tumors. Two patients received sacituzumab tirumotecan, a related agent. Patients were divided into three groups: 60 received the antibody-drug conjugate alone, 13 received it together with the PD-1 inhibitor pembrolizumab, and 14 received a triple-agent regimen combining the antibody-drug conjugate, pembrolizumab, and the oral anti-angiogenic drug apatinib. All patients received at least two cycles of therapy in the second-line or later setting.

The results describe a clear stepwise gradient of activity. The objective response rate was 31.7 percent with monotherapy, 38.5 percent with the dual combination, and 57.1 percent with the triple-agent regimen. Disease control rates followed the same pattern, rising from 78.3 percent to 84.6 percent and then to 92.9 percent. More consequential still were the survival figures. Median progression-free survival was 3.8 months with monotherapy, 10.0 months with the dual combination, and 15.4 months with the triple-agent combination, over a median follow-up of 15.2 months. In pooled analysis, any combination therapy was associated with a hazard ratio of 0.387 for progression or death compared with monotherapy, and the benefit persisted after propensity-score-based overlap weighting, with an adjusted hazard ratio of 0.49.

The biological logic underlying the triplet is rooted in the interplay between tumor vasculature and antitumor immunity. Low-dose VEGF pathway inhibition is known to promote vascular normalization within tumors, reversing the hypoxic, immunosuppressive microenvironment that blunts immune checkpoint blockade. Preclinical work has shown that anti-angiogenic therapy enhances CD8-positive T cell activity, and that the OPN-TGF-beta pathway upregulates PD-1 on these T cells, increasing their sensitivity to PD-1 blockade. Clinical evidence has been accumulating in parallel: the ATRACTIB trial suggested that adding bevacizumab to atezolizumab and paclitaxel improved outcomes including in PD-L1-negative disease, and a multicenter phase II trial of camrelizumab, apatinib, and eribulin achieved a 37 percent response rate in heavily pretreated patients regardless of PD-L1 status. The new study extends this concept to an antibody-drug conjugate backbone.

Importantly, the exploratory subgroup analyses suggested that the activity of the triple-agent combination may not be confined to PD-L1-positive tumors. The interaction P-value between treatment effect and PD-L1 status was 0.098, and among the 39 patients with confirmed PD-L1-positive disease, median progression-free survival had not been reached in the triplet group compared with 5.0 months on monotherapy, a statistically significant difference. Prior treatment with a PD-1 inhibitor, documented in roughly half of the cohort, also did not appear to diminish the benefit of the triplet, with an interaction P-value of 0.828. This is clinically meaningful because primary resistance to checkpoint inhibitors occurs in approximately 60 percent of PD-L1-negative triple-negative breast cancers, and immunotherapy rechallenge after progression is often viewed with skepticism.

One of the most intriguing findings emerged from an interaction test involving prior platinum exposure. Among patients who had previously received platinum chemotherapy, the hazard ratio for the triple-agent regimen versus monotherapy was 0.19, a dramatic reduction in the risk of progression or death, whereas among platinum-naive patients the hazard ratio was 1.11, showing essentially no difference. The interaction P-value of 0.039 suggests that platinum-pretreated patients may represent a subgroup particularly likely to benefit from the triplet, possibly because platinum sensitivity reflects underlying DNA damage repair deficiencies that also influence antibody-drug conjugate efficacy. The authors caution that this observation is exploratory and requires prospective validation, but it provides a concrete hypothesis for patient selection in future trials.

Safety data were reassuring. With prophylactic measures applied across the entire cohort, grade 3 or higher treatment-related adverse events occurred in 20.0 percent of monotherapy patients, 15.4 percent of the dual-combination group, and 14.3 percent of the triple-agent group, a difference that was not statistically significant. The most common severe toxicities were leukopenia and neutropenia across all groups. No treatment-related deaths were recorded, and no grade 3 or higher febrile neutropenia, hyperbilirubinemia, rash, or oral ulceration was reported. The starting dose of the antibody-drug conjugate was individualized according to performance status, with patients scoring 2 on the Eastern Cooperative Oncology Group scale receiving reduced starting doses below 80 percent of the standard level. Notably, an antibody-drug conjugate starting dose of at least 80 percent was associated with improved progression-free survival, underscoring the importance of maintaining dose intensity where tolerable.

Beyond the clinical outcomes, the research team developed an exploratory genomic scoring system aimed at identifying which patients are most likely to respond to the triple-agent strategy. The system incorporates mutations in 17 genes connected to Trop-2 antibody-drug conjugate sensitivity, homologous recombination repair, and angiogenesis pathways. Genes promoting therapeutic response, such as ATR, which may sensitize tumors to topoisomerase I inhibition and correlate with higher mutational burden and immunotherapy benefit, received positive weighted scores, while resistance-associated genes received negative scores. Patients whose total score exceeded zero were classified as likely to benefit from the triplet, and Fisher’s exact testing showed the classification was statistically significant. Genes such as VEGFRA and VEGFRB, tied to angiogenesis signaling, may indicate sensitivity to the anti-angiogenic component. The authors emphasize that the model’s principal value at this stage is hypothesis generation rather than clinical deployment.

The study also confirmed several prognostic patterns familiar from earlier research. Patients who initiated antibody-drug conjugate therapy in the second or third line had significantly longer progression-free survival than those treated later, at 5.8 versus 3.0 months. The presence of liver metastases, brain metastases, or visceral disease more broadly each independently predicted shorter progression-free survival after multivariable adjustment, with hazard ratios of 2.38, 2.51, and elevated risk for visceral involvement overall. These findings reinforce that disease biology and metastatic pattern remain dominant determinants of outcome even in the era of antibody-drug conjugates, and they highlight the need for improved risk stratification in biologically aggressive disease.

The investigators are transparent about the limitations inherent in a retrospective, single-center, non-randomized design. Selection bias and residual confounding cannot be excluded, baseline characteristics such as treatment line and PD-L1 status differed descriptively across groups, and the small size of the combination cohorts, 13 and 14 patients respectively, limits statistical power. Sensitivity analyses restricted to second- or third-line patients yielded directionally consistent but non-significant results, likely reflecting reduced sample size. To address these constraints, the team has launched a prospective randomized controlled trial, registered as NCT06851299, designed to rigorously test the efficacy and safety of Trop-2 antibody-drug conjugate-based combination regimens and to validate the genomic risk score. If those results confirm the signals described here, a triplet regimen combining a Trop-2 antibody-drug conjugate, PD-1 blockade, and anti-angiogenic therapy could reshape the treatment algorithm for one of breast cancer’s most lethal forms, extending meaningful survival to patients who currently have few good options.

Subject of Research: Trop-2-directed antibody-drug conjugate monotherapy and combination therapy for pretreated metastatic triple-negative breast cancer

Article Title: Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study

Article References: Liu, J., Ding, L., Wang, J., Chen, T., Long, T., Li, Q., Chai, J., Yao, H., Wang, Y., & Zhao, J. (2026). Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study. Breast Cancer Research and Treatment, 219(2), Article 10. https://doi.org/10.1007/s10549-026-08070-9

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08070-9

Keywords: Trop-2 antibody-drug conjugates, metastatic triple-negative breast cancer, sacituzumab govitecan, PD-1 inhibitors, anti-angiogenic therapy, triple-agent combination therapy, pembrolizumab, apatinib, progression-free survival, biomarker-guided therapy, real-world study, immune checkpoint inhibitors

The study, called EVERGREEN, analyzed outcomes for 207 women whose estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer had progressed after treatment with a CDK4/6 inhibitor. Of these patients, 150 received everolimus alongside endocrine therapy, while 57 received endocrine therapy without everolimus. After a median follow-up of 31.8 months, the median real-world progression-free survival was 5.0 months in the everolimus group, compared with 4.3 months among those given endocrine therapy alone. The adjusted hazard ratio for progression or death was 0.68, with a 95 percent confidence interval of 0.47 to 0.99.

That result means the everolimus-containing treatment was associated with an approximately 32 percent lower relative risk of progression or death during the study period after statistical adjustment. It does not mean that every patient gained a fixed additional 32 percent of survival, nor that the cancer was controlled for 32 percent longer. The absolute difference in median progression-free survival was only 0.7 months—roughly three weeks. The researchers therefore describe the benefit as modest. There was no statistically significant improvement in the time until chemotherapy was needed or in overall survival, the measure that most directly captures whether treatment helps patients live longer.

Everolimus attacks a different part of the machinery that cancer cells use to grow. It inhibits mammalian target of rapamycin, or mTOR, a central signaling protein that helps regulate protein production, cell growth, metabolism and survival. In hormone receptor-positive breast cancer, signaling through the estrogen receptor can cooperate with the PI3K–AKT–mTOR pathway to keep malignant cells dividing even when estrogen-driven growth is being suppressed. Laboratory studies have suggested that increased activity in this pathway can contribute to resistance against CDK4/6 inhibition. By blocking mTOR while continuing endocrine therapy, clinicians aim to shut down a bypass route that cancer cells may exploit after cell-cycle treatment stops working.

The biological rationale, however, does not guarantee a large clinical effect. Tumors that acquire resistance to CDK4/6 inhibitors are not uniform. Some develop alterations in genes such as ESR1, which encodes the estrogen receptor; others involve the PI3K–AKT–mTOR network, including PIK3CA, AKT1 or PTEN. Still others may become less dependent on estrogen signaling altogether, switch to alternative growth programs or contain several resistant subclones at once. Everolimus may be most useful when the mTOR pathway remains an important engine of tumor growth, but the EVERGREEN study did not establish a biomarker that could reliably identify such patients before treatment.

The study’s design is important for interpreting its findings. EVERGREEN was a multicentre, international, retrospective quasi-experimental study rather than a randomized clinical trial. The investigators compared women treated at centers where everolimus plus endocrine therapy was the standard approach with women treated at centers where endocrine therapy alone was standard. This approach can provide valuable evidence from routine oncology practice, especially when randomized trials have not answered a specific treatment question. It also introduces potential sources of bias: treatment policies differ between hospitals, physicians may select everolimus for particular types of patients, and medical records may not capture every factor influencing treatment choice or disease assessment.

The patient groups were broadly balanced at baseline, according to the researchers, but the everolimus cohort had received a greater number of previous lines of therapy. That imbalance matters because heavily pretreated disease can be more biologically resistant and patients may have poorer overall health or fewer remaining treatment options. The investigators used adjusted analyses to account for measured differences, but statistical methods cannot completely remove the effects of unknown or unrecorded factors. “Real-world progression-free survival” is also less tightly controlled than progression-free survival in a prospective trial, where imaging schedules, response assessments and follow-up procedures are standardized.

The safety findings were consistent with earlier reports of everolimus, but the abstract does not provide a detailed breakdown of adverse events. The drug can cause mouth inflammation, rash, fatigue, diarrhea, metabolic changes and suppression of blood-cell production; it can also produce noninfectious pneumonitis, an inflammatory lung complication. These risks are particularly relevant in advanced cancer, where maintaining quality of life is a central treatment goal. A therapy that delays progression by several weeks may be worthwhile for a carefully selected patient who wants to remain on oral treatment and has limited alternatives, but less attractive for someone vulnerable to complications or eligible for a better-matched molecular therapy.

The findings arrive in a rapidly changing treatment landscape. After CDK4/6 inhibitor progression, options may include endocrine drugs designed to target specific resistance mutations, inhibitors of PI3K or AKT signaling, antibody–drug conjugates and chemotherapy. For example, the presence of an ESR1 mutation or an alteration in PIK3CA, AKT1 or PTEN may influence the suitability of other targeted approaches, although the best sequence of therapies is still evolving. The EVERGREEN results do not show that everolimus should replace these options. Instead, they suggest that it remains a possible strategy for a subset of patients whose disease is still endocrine-sensitive and for whom the expected benefits outweigh the drug’s side effects.

The study also illustrates why treatment after CDK4/6 resistance cannot be reduced to a single universal prescription. A median benefit measured in weeks can conceal meaningful differences between individuals: some patients may experience little response, while others may achieve substantially longer disease control. Future trials will need to connect outcomes to tumor biology, circulating tumor DNA, prior endocrine exposure and the pattern of progression. For now, EVERGREEN provides a cautiously encouraging but not practice-revolutionizing message: everolimus can add a small amount of control after CDK4/6 inhibitors, but the decision to use it should be individualized rather than automatic.